MALNC: a new mutant NPM1/IDH2R140 and PML-RARA-associated lncRNA with impact on AML cell proliferation, maturation and drug response.
JSON
Cozzi E, Neddermeyer A, Zhong X, Gamboa-Cedeño AM, Kanellis DC, Österroos A, Björklund M, Struyf N, Karlsson K, Qu Y, Månsson A, Pandzic T, Bengtzén S, Nilsson C, Fiskesund R, Baliakas P, Erkers T, Bartek J, Kallioniemi OP, Qian H, Lennartsson A, Lehmann S
Cancer Gene Ther - (-) - [2025-08-23; online 2025-08-23]
As the non-coding genome remains poorly characterized in acute myeloid leukemia (AML), we aimed to identify and functionally characterize novel long non-coding RNAs (lncRNAs) relevant to AML biology and treatment. We first identified lncRNAs overexpressed in AML blasts and, among them, discovered a novel transcript, which we named myeloid and AML-associated intergenic long non-coding RNA (MALNC). MALNC is overexpressed in AML, particularly in cases with the PML-RARA fusion or IDH2R140/NPM1 co-mutations, and is associated with a distinct gene expression profile. Functional studies showed that MALNC knockout impairs AML cell proliferation and colony formation, enhances ATRA-induced differentiation, and sensitizes cells to arsenic trioxide. Transcriptomic analysis revealed that MALNC loss alters the expression of retinoic acid pathway genes, and chromatin binding studies showed that MALNC binds to genes related to the retinoic acid and Rho GTPase pathways. In conclusion, we have identified MALNC as a novel lncRNA that promotes leukemic cell proliferation, counteracts ATRA-induced differentiation, and modulates drug sensitivity in AML.
NGI Uppsala (SNP&SEQ Technology Platform) [Service]
National Genomics Infrastructure [Service]
PubMed 40849353
DOI 10.1038/s41417-025-00954-0
Crossref 10.1038/s41417-025-00954-0
pii: 10.1038/s41417-025-00954-0